3 shares for the post-pandemic biotechnology boom

Andrea Jankelow
November 17, 2021

Pfizer or Modern? J&J or AstraZeneca? Before Covid, when was the last time you asked anyone what kind of vaccine they were getting?

The pandemic has revolutionized medicine and biotechnology – and investors have experienced huge profits as a result. BioNTech has increased more than 22X in just two years. Modern has risen over 28X in the same period.

Industry insiders now believe the pandemic has accelerated the emergence of the biotech sector by as much as a full decade.

We at The Motley Fool have traditionally stayed away from biotech stocks because they were unpredictable. But we truly believe this is one of the best new sectors to invest right now.

Wall Street Journal even said, Just as the digital revolution drove innovation in the latter half of the 20th century, the biotechnological revolution will drive the first half of the 21st century. Children who study digital coding will be surpassed by those who study the code of life. ”

Suffice it to say that biotechnology will be big money-making stuff. But many investors believe that it is too complex to even try to argue, which means that many of these lesser-known biotech technologies often remain undervalued for a very, very long time …

In fact, the majority there are no vaccines have been knocked down over the past year, which has led to attractive access points – if you know where to look.

Our team of analysts over at Breakers – the same team that predicted Mercadolibre in 2009 (op 11,460 th most common%, Tesla in 2011 (op 16,011%, and Shopify in 2016 (op 7,781%, has identified three biotech stocks that we believe are set up for explosive growth in the coming years.

One of them, an underdog who was not in favor, was in messenger RNA (mRNA) long before mRNA was cool. New things in the pipeline have it lined up to be a possible breakout star at a great price.

Another choice provides remarkable potential for growth due to their monopoly over the market for one particular chronic disease (and patents that do not expire for a long time). They are also starting to grow into new medical sectors. Investors here will find a solid steady-state business at what we believe is an undervalued price, with room to grow and take on so much more.

Our analysts’ third choice includes two of the hottest words in biotechnology right now: antibodies and cancer. But they have the science and medicine to support the buzz – in fact, they even have a new drug under FDA review, which could mean an increase in profits in the coming years.

We have all the details about these shares in our new biotech report, which is available for free to members of Breakers. And with our 30-day full money-back guarantee, you have nothing to lose. If the service is not right for you, no sweat – but you will get to keep the report (and information about the three stocks we reveal inside) as our gift to you.

For information on how to participate Breakers – and learn about why we believe these three stocks will be breakout winners in a post-Covid world – just enter your email address below.

Returns are updated during market hours. The Motley Fool owns shares in MercadoLibre and Tesla. The Motley Fool has a disclosure policy.

The Motley Fool respects your privacy and strives to be transparent about our data collection practices. We use your information to customize the site for you, to contact you about your membership, to provide you with promotional information and collectively to help us better understand how the service is used.

Past performance is not a predictor of future performance. Individual investment results may vary. All investment involves the risk of loss.

Confidentiality / legal information.

Leave a Comment